Generic Name and Formulations:
Ceftriaxone sodium 500mg, 1g; IM or IV inj; sodium content 3.6mEq/g.
Roche Diagnostics Corp.
Indications for ROCEPHIN:
Susceptible bacterial septicemia, acute bacterial otitis media, lower respiratory tract, UTIs, skin and skin structure, bone and joint, pelvic inflammatory disease (PID), intraabdominal infections, meningitis, uncomplicated gonorrhea. Surgical prophylaxis.
1–2g IM or IV once daily or in 2 equally divided doses; max 4g/day. Gonorrhea: 250mg IM once. Surgery: a single dose of 1g IV ½–2 hours pre-op.
50–75mg/kg per day in equally divided doses every 12hrs; max 2g/day. Skin and skin structures: may give once daily or in 2 equally divided doses every 12hrs; max 2g/day. Meningitis: 100mg/kg (max 4g) for 1 dose, then 100mg/kg per day (max 4g/day) once daily or in 2 equally divided doses every 12hrs for 7–14 days. Otitis media: 50mg/kg (max 1g) IM once.
Hyperbilirubinemic or premature neonates. Concomitant calcium-containing IV solutions or products in neonates. Ceftriaxone solutions containing lidocaine for IV administration.
Penicillin or other beta-lactam allergy. Discontinue if urolithiasis, oliguria, renal or gallbladder sonographic abnormalities, signs or symptoms occur. Renal failure: monitor; decrease dose if drug accumulation occurs. Chronic hepatic disease or malnutrition (impaired Vit. K synthesis or storage): monitor prothrombin time. Both hepatic and significant renal impairment: usual max 2g/day. GI disease (esp. colitis). Ensure adequate hydration. Pregnancy (Cat.B). Nursing mothers.
See Contraindications. Increase risk of bleeding with concomitant Vit. K antagonists. May be potentiated by probenecid. Precipitation can form with calcium-containing solutions; avoid. May cause false (+) Clinitest or Coomb's test.
Local reactions, hematologic effects (eg, eosinophilia), rash, diarrhea, elevated liver enzymes; rare: hemolytic anemia, allergic pneumonitis, seizures, anaphylaxis, pancreatitis.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|